BioCentury
ARTICLE | Company News

Merck KGaA, Pfizer, Accelerated Cure Project autoimmune news

September 15, 2014 7:00 AM UTC

Merck's EMD Serono Inc. biopharmaceutical division is providing at least $1 million in funding to the non-profit for a longitudinal U.S. study focused on obtaining real-world data from multiple sclerosis patients. The Optimizing Treatment -- Understanding Progression (OPT-UP) study, slated to start in 1Q15, will enroll 2,500 MS patients and follow them for up to five years to collect data to help optimize treatment and understand progression. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article